Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$56.93
-1.0%
$58.42
$42.52
$62.89
$116.26B0.2612.05 million shs12.07 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$76.81
-0.4%
$68.37
$30.02
$80.20
$9.56B0.382.21 million shs1.97 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$33.30
-0.7%
$32.59
$12.15
$39.96
$3.58B0.251.03 million shs1.76 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.97%-1.41%-0.40%-5.68%+23.01%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+1.13%-2.06%+25.24%+23.18%+152.70%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-0.06%+2.19%+9.46%+13.08%+134.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$56.93
-1.0%
$58.42
$42.52
$62.89
$116.26B0.2612.05 million shs12.07 million shs
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$76.81
-0.4%
$68.37
$30.02
$80.20
$9.56B0.382.21 million shs1.97 million shs
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
$33.30
-0.7%
$32.59
$12.15
$39.96
$3.58B0.251.03 million shs1.76 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
-0.97%-1.41%-0.40%-5.68%+23.01%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+1.13%-2.06%+25.24%+23.18%+152.70%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-0.06%+2.19%+9.46%+13.08%+134.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.37
Hold$61.317.70% Upside
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.86
Moderate Buy$99.3029.28% Upside
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
2.89
Moderate Buy$39.6719.12% Upside

Current Analyst Ratings Breakdown

Latest BMY, CYTK, and EWTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/28/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
Reiterated RatingBuy
5/18/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Initiated CoverageOutperformBuy$99.00
5/18/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
UpgradeOutperformStrong-Buy
5/12/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetOverweight$92.00 ➝ $97.00
5/11/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetBuy$136.00 ➝ $140.00
5/7/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetOverweight$95.00 ➝ $105.00
5/6/2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
Set Price Target$52.00
5/6/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetOverweight$90.00 ➝ $103.00
5/6/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Set Price Target$119.00
5/6/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetOutperform$101.00 ➝ $119.00
5/6/2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Boost Price TargetBuy$98.00 ➝ $108.00
(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$48.48B2.40$7.97 per share7.14$9.84 per share5.79
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$88.04M108.56N/AN/A($6.64) per share-11.57
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/A$4.58 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$7.05B$3.5615.999.380.1715.01%64.87%13.16%7/30/2026 (Estimated)
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)

Latest BMY, CYTK, and EWTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
-$0.50-$0.46+$0.04-$0.46N/AN/A
5/5/2026Q1 2026
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million
4/30/2026Q1 2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$1.42$1.58+$0.16$1.31$10.93 billion$11.49 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
$2.524.43%+1.61%70.79%17 Years
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/AN/AN/AN/AN/A

Latest BMY, CYTK, and EWTX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/2/2026
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
quarterly$0.634.23%4/2/20264/2/20265/1/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
2.10
1.42
1.28
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
4.21
4.21
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A
22.61
22.61

Institutional Ownership

CompanyInstitutional Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
76.41%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
0.05%
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.60%
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
23.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
32,5002.04 billion2.04 billionOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
250124.43 million121.20 millionOptionable
Edgewise Therapeutics, Inc. stock logo
EWTX
Edgewise Therapeutics
60107.59 million82.63 millionOptionable

Recent News About These Companies

Edgewise Therapeutics (EWTX) Receives a Buy from Wedbush

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bristol Myers Squibb stock logo

Bristol Myers Squibb NYSE:BMY

$56.93 -0.59 (-1.03%)
Closing price 03:59 PM Eastern
Extended Trading
$56.85 -0.08 (-0.14%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

Cytokinetics stock logo

Cytokinetics NASDAQ:CYTK

$76.81 -0.34 (-0.44%)
Closing price 04:00 PM Eastern
Extended Trading
$77.27 +0.46 (+0.60%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Edgewise Therapeutics stock logo

Edgewise Therapeutics NASDAQ:EWTX

$33.30 -0.24 (-0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$33.28 -0.02 (-0.06%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.